Advances in the Development of Antibiotic Drug Candidates for Urinary Tract Infection Therapy
Abstract
Urinary tract infections (UTIs) remain one of the most prevalent bacterial infections worldwide, and their complications are increasingly exacerbated by antibiotic resistance. The predominant pathogen, Escherichia coli (E. coli), contributes to both uncomplicated and complicated infections through adhesion and biofilm formation, posing major therapeutic challenges. This review critically examines current and emerging antibiotic drug candidates for UTI therapy, integrating insights from microbiology, clinical studies, and medicinal chemistry. Existing antibiotics for UTI treatment include trimethoprim/sulfamethoxazole, nitrofurantoin, fosfomycin, ciprofloxacin, levofloxacin, cephalexin, ceftriaxone, amoxicillin/clavulanate, doxycycline, and piperacillin/tazobactam. Additionally, Orlynvah and Pivya, two recently approved antibiotics, are discussed for their potential use in UTI therapy. The review also discusses structure-activity relationship (SAR)-guided development of trimethoprim derivatives and heterocyclic analogues targeting dihydrofolate reductase (DHFR), with docking and mechanistic studies proposed for future evaluation. Nonantibiotic strategies, such as mannosides, curli inhibitors, and FimH antagonists, are also being explored as promising anti-adhesion and biofilm-targeting therapies. This review emphasizes the urgent need for novel, resistance-resilient antibacterial agents and highlights recent chemical and biological innovations that could transform future UTI…
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.